Investment Thesis
Aurinia demonstrates exceptional profitability fundamentals with 53.3% operating margins and 44.2% net margins, coupled with solid 20.4% YoY revenue growth. The balance sheet is fortress-like with zero meaningful debt, strong liquidity (5.55x current ratio), and consistent free cash flow generation ($32.6M FCF). Primary concerns center on modest capital efficiency (6.1% ROE) and pharmaceutical sector risks.
Strengths
- Exceptional profitability margins (53.3% operating, 44.2% net) well above pharma industry averages
- Strong balance sheet with zero debt (D/E 0.00x), excellent liquidity (5.55x current ratio), and $567.6M equity base
- Consistent free cash flow generation (41.9% FCF margin) indicating sustainable business model
- Solid revenue growth at 20.4% YoY with profitability scaling
- No financial distress indicators (16.7x interest coverage, manageable debt load)
Risks
- Low return on equity (6.1%) and ROA (4.7%) suggest inefficient capital deployment despite strong margins
- Pharmaceutical company inherent risks: clinical trial failures, regulatory setbacks, patent cliffs
- Modest cash position ($40.7M) relative to asset base may constrain growth investments
- Missing gross margin data limits visibility into production cost structure
- Relatively small revenue base ($77.7M) with limited scale
Key Metrics to Watch
- Revenue growth sustainability and gross margin trends
- Operating cash flow trajectory and capital allocation strategy
- Return on equity improvement as company scales
- R&D pipeline progress and clinical trial outcomes
Financial Metrics
Revenue
77.7M
Net Income
34.4M
EPS (Diluted)
$0.25
Free Cash Flow
32.6M
Total Assets
724.0M
Cash
40.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
53.3%
Net Margin
44.2%
ROE
6.1%
ROA
4.7%
FCF Margin
41.9%
Balance Sheet & Liquidity
Current Ratio
5.55x
Quick Ratio
5.01x
Debt/Equity
0.00x
Debt/Assets
21.6%
Interest Coverage
16.70x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:50:21.246341 |
Data as of: 2026-03-31 |
Powered by Claude AI